Plasma zinc concentration (PZC) is a recommended biomarker to assess zinc status and the risk of zinc deficiency in populations. However, the relation between PZC and clinical signs of zinc deficiency remains uncertain. These analyses were conducted to evaluate the relation between PZC and clinical signs of zinc deficiency and to determine a cutoff for PZC below which individuals would have an increased likelihood of having clinical signs associated with zinc deficiency.
Introduction
The WHO/UNICEF/International Atomic Energy Agency/ International Zinc Nutrition Consultative Group and the EURopean micronutrient RECommendations Aligned Network of Excellence (EURRECA) recommend the measurement of plasma zinc concentration (PZC) 5 as a biomarker to assess zinc status and the population risk of zinc deficiency (1) (2) (3) . Reference values for PZC are based on the distribution of values obtained from a nationally representative survey, conducted in apparently healthy individuals with presumed adequate zinc nutrition and status in the United States (NHANES II). Cutoffs for zinc deficiency (lower limits of normal) are statistically defined on the basis of the 2.5th percentile of PZC stratified by age group, sex, and time of day of blood collection and fasting status (57-65 mg/dL for children <10 y, 61-74 mg/dL for males $10 y, and 59-70 mg/dL for females $10 y) (4) . However, the relation between PZC and clinical signs of zinc deficiency remains uncertain. Therefore, we analyzed available information from dietary zinc depletion studies and case reports of acrodermatitis enteropathica (AE) to establish the relation between PZC and clinical evidence of zinc deficiency and to further assess the utility of PZC as a biomarker of zinc nutrition.
Experimental studies of moderate and severe dietary zinc restriction have been conducted in individuals with presumably adequate zinc intakes and status at baseline, to study zinc metabolism and to define dietary zinc requirements (4, 5) . Although the intended objective of these studies was to assess zinc requirements by determining the amount of zinc that must be absorbed to offset the amount of endogenous zinc lost from intestinal and nonintestinal routes, clinical signs considered to be associated with zinc deficiency (e.g., dermatologic lesions, diarrhea) were reported among participants during the period of zinc depletion, with concurrent time-course measures of PZC (5) . Additional data on clinical signs of zinc deficiency and PZC are provided by case reports of individuals with AE. AE is an autosomal recessive disorder caused by a mutation in the solute carrier family 39 (zinc transporter), member 4 (SLC39A4) gene, consequently reducing the synthesis of the zinc transporter Zrt, Irt-like protein 4 (ZIP4); this results in defective absorption of dietary zinc and severe zinc deficiency (6) . Clinical manifestations include the ''classical triad'' of deficiency signs (severe dermatologic lesions, alopecia, and diarrhea), as well as endocrine, ophthalmic, and neurobehavioral abnormalities (7) . High-dose zinc supplementation ($1-3 mg elemental zinc Á kg 21 Á d 21 ) results in rapid resolution of clinical signs and increases in PZC (8) .
The objectives of the present analyses were as follows: 1) to evaluate the relation between PZC and clinical signs of zinc deficiency and 2) to determine a cutoff for PZC below which individuals would have an increased likelihood of having clinical signs associated with severe zinc deficiency.
Methods

Overview
The present analyses use data available from previously conducted experimental zinc depletion-repletion studies and case reports of individuals with AE. The following sections describe the search strategies for the identification of studies, criteria for inclusion and exclusion, and methods of data extraction and analysis.
Depletion-repletion studies Search strategy for identification of studies. To identify experimental, controlled zinc depletion (and repletion) trials, the PubMed database was searched from inception to November 2013 by using the following search terms: ''zinc AND (plasma OR serum) AND deplet*''; searches were restricted to human studies. In addition, 1 expert (J.C.K.) was asked to identify additional studies for review, which were then subjected to the same inclusion criteria as articles identified via PubMed.
Criteria for inclusion of studies. The title and abstract of each identified article were screened by a single reviewer (K.R.W.), and complete articles were obtained if the available information suggested that the article described an experimental, controlled zinc depletionrepletion trial. To be included, the study needed to meet the following criteria: 1) participants were apparently healthy with adequate zinc intake and status at baseline, 2) participants underwent an experimental period of severe or moderate dietary zinc restriction (<1 RDA), 3) participants resided in a clinical setting with controlled diet and monitoring during the periods of dietary modification, 4) PZC was measured at a minimum of 2 time points, 5) at least 1 participant in the study developed clinical signs considered to be associated with zinc deficiency, and 6) the time of onset of clinical signs was reported in relation to PZC. Clinical signs considered to be associated with zinc deficiency included dermatitis (skin lesions/acne that remained for the duration of the depletion period after first occurrence and either improved with zinc repletion or were followed by subsequent clinical signs), aphthous stomatitis (canker sores), pharyngitis (sore, inflamed throat), and diarrhea.
Data extraction. Data for each included study were extracted into a standardized Microsoft Excel spreadsheet by a single reviewer (K.R.W.) and discussed with coinvestigators. Extracted data included the following: age, sex, study day, PZC at each measured time point (estimated from figures if not otherwise reported), and the presence or absence of clinical signs reported by study day. PZCs at 2 time points were selected for subsequent analyses. Baseline measurements were considered to be the last available PZC before the start of the depletion period or, if the former measurement was not available, the first PZC measured during the depletion period (days 0-8). Depletion measurements were considered to be the PZC at the time of the first appearance of any clinical sign; among individuals who did not develop clinical signs during the entire depletion period, depletion measurements were considered to be the lowest PZC of the depletion period.
Acrodermatitis enteropathica
Search strategy for identification of studies. To identify case reports on individuals with AE, we used a strategy similar to the aforementioned electronic bibliographic search. PubMed, EMBASE, and CINAHL Plus and Academic Search Complete (via EBSCO) databases were searched from inception to April 2013; the expanded set of databases was used to better capture case reports included in conference proceedings, foreign language publications, etc. Search terms included ''acrodermatitis enteropathica'' and 1 of the following combinations: 1) ''zinc AND plasma,'' 2) ''zinc AND serum,'' or 3) ''hypozincemia''; searches were restricted to human studies.
Criteria for inclusion of studies. The title and abstract of each identified article were screened by a single reviewer (K.R.W.) and discussed with coinvestigators, and complete articles were obtained if the available information suggested the article pertained to primary AE [due to a confirmed or suspected genetic mutation of SLC39A4. To be included, an article needed to meet the following criteria: 1) case report (cross-sectional or longitudinal) or quasi-experimental study of primary AE in an individual or individuals, 2) reported clinical signs (either before initiation of zinc supplementation or after withdrawal of supplements) that were responsive to zinc supplementation, 3) reported PZC at a minimum of 1 time point, 4) participant was currently not undergoing treatment with quinoline derivatives and was symptom free at the time PZC was measured (before the understanding of the role of zinc in AE, quinoline derivatives were standard treatment, resulting in partial or complete resolution of symptoms but not necessarily increased PZC), and 5) not a previously reported case (such that individual cases were only included once). Studies that provided additional longitudinal information regarding the association of within-in subject changes in PZC after treatment and the presence or absence of clinical signs were eligible for inclusion in longitudinal analyses if they 1) met the aforementioned inclusion criteria, 2) reported PZC at a minimum of 3 time points, 3) reported a resolution or reoccurrence of clinical signs taking place between each measure, and 4) reported the timing of the onset/remission of clinical signs in relation to the measurement of PZC. Articles were included if they were written in English, French, Spanish, or German; if only an English-language abstract was available for a study, it was included if it met the criteria listed above.
Specific exclusion criteria were as follows: 1) acquired or transient zinc deficiency due to total parenteral nutrition, a specific disease state (e.g., Crohn disease), preterm birth, or low breast-milk zinc content or 2) variant AE responsive to picolinic acid alone.
Data extraction. Data for each included study were extracted into a standardized Excel database (Microsoft) by a single reviewer (K.R.W.). Extracted data included age, age at onset of symptoms, sex, genetic mutation/family history, presence or absence of categorical clinical signs based on a 3-category model (dermatologic lesions, alopecia, diarrhea) or a 5-category model (dermatologic, gastrointestinal, ophthalmologic, neurological-behavioral, endocrine), and PZC (estimated from graphs if necessary). If >1 PZC was reported for an individual during 1 exacerbation episode or clinical remission, the following criteria were used to select the PZC value included in the analyses: 1) when clinical signs were present, the PZC reported immediately preceding the start of high-dose Plasma zinc and clinical zinc deficiency 1205 zinc supplementation was included; 2) when clinical signs were absent, the first PZC obtained after initiation of high-dose zinc supplementation and with at least partial remission of clinical signs of zinc deficiency was used. For experimental studies, PZCs immediately preceding the withdrawal of zinc supplements and at the first onset of clinical signs were selected. Finally, for longitudinal data, the maximum and minimum PZC from each period of exacerbation or remission of clinical signs, respectively, was selected.
Data analyses
The main outcome of interest, for both the zinc depletion-repletion and AE studies, was the relation between PZC and clinical signs of zinc deficiency. Descriptive statistics were calculated for all variables; variables not normally distributed (namely, PZC among individuals with AE) were transformed before subsequent analysis. Relations between PZC (with and without clinical signs) and baseline demographic characteristics (age, sex) and the presence of specific clinical signs (AE) were evaluated by using mixed linear models, allowing for random effects (intercept and slope) of the independent variable by study. Relations between age and the presence of specific clinical signs (AE) were evaluated by using Rao-Scott chi-square goodness-of-fit tests, with study as a cluster variable.
Interindividual differences in PZCs (pre-and postdepletion) among those who did or did not develop clinical signs associated with zinc deficiency were evaluated by using mixed linear models, allowing for random effects by study, and the Wilcoxon rank-sum test as appropriate (zinc depletion-repletion studies only). Intraindividual changes in PZC (with and without clinical signs; pre-and post-severe dietary zinc restriction or high-dose zinc treatment) were evaluated by using mixed linear models, allowing for random effects in the independent variable (intercept and slope) by both study and participant. Nonparametric kernel density estimate plots were used to examine smoothed distributions of continuous PZCs by time point and clinical presentation (lower bound: 0 mg/dL; upper bound: 200 mg/dL; bandwidth: 1). Indexes based on the overlap of PZCs among those with and without clinical signs were calculated by using a method proposed by Hartz (9) . Initially, generalized linear mixed models were used to estimate the probability of clinical signs being present at a particular PZC; when there was no clustering by study or participant level, logistic regression analyses were used.
The AUCs of receiver operating characteristic (ROC) plots were calculated to assess the overall ability of PZC to predict clinical zinc deficiency over a range of PZC cutoffs (SAS PROC LOGISTIC). When clustering by participant level was present, conservative estimates of the AUC and its confidence limits were obtained on the basis of a simulation model in which 1 PZC was randomly selected for each individual over 10,000 iterations. Sensitivity was calculated as the percentage of those with clinical signs who were correctly identified by PZC as having clinical zinc deficiency (true positives). Specificity was calculated as the percentage of individuals without clinical signs who were correctly identified by PZC as not having clinical zinc deficiency (true negatives).
All statistical analyses were completed by using SAS System for Windows release 9.3 (SAS Institute). A P value <0.05 was considered significant. PZCs are presented in mg/dL (to convert to mmol/L, multiply by 0.153). Data are presented as means 6 SDs or medians (IQRs) unless otherwise noted.
Results
Zinc depletion-repletion studies. By using the aforementioned search strategy, 93 articles were initially identified and reviewed; 4 unique studies met the inclusion criteria, with data available for a total of 29 individuals aged 18-40 y ( Table 1 ) (10) (11) (12) (13) (14) (15) . In all of the identified studies in which at least 1 participant developed clinical signs considered to be associated with zinc deficiency, participants underwent severe dietary zinc restriction (<1 mg Zn/d) for periods ranging from 15 to 63 d. The baseline PZC was 82.3 6 14.8 mg/dL and did not differ by age (P = 0.50) or sex (P = 0.97). Dietary zinc was added to a semipurified formula (resulting in a higher bioavailability of zinc).
During the course of the depletion period, 17 individuals developed clinical signs potentially linked to zinc deficiency (dermatologic lesions, n = 11; aphthous stomatitis, n = 11; diarrhea, n = 2; and pharyngitis, n = 9); the first onset of clinical signs among these individuals occurred within 12-36 d of the beginning of the depletion period. Among those who developed clinical signs, the PZC at the first onset of clinical signs was 36.0 6 16.8 mg/dL and was 46.6% (40.3-59.7%) of baseline values. Among those who remained asymptomatic, the low PZC during the depletion period was 67.9 6 13.3 mg/dL and was 73.8% (67.2-80.0%) of baseline concentrations. PZCs were significantly lower among those who developed clinical signs than among those who did not (P = 0.034) (Fig. 1A) . The overlap index for PZC among those with and without clinical signs was 0.14. Logistic regression indicated that with progressively lower PZC, there was an increased likelihood of clinical signs being present; for every 1-SD decrease in PZC, the odds of having clinical signs increased by a factor of 13.7 (95% CI: 2.4, 78.8; P = 0.0033) (Fig. 1B) . In comparison to those who remained asymptomatic, the individuals who developed clinical signs had a lower baseline PZC (75.7 6 14.9 vs. 91.7 6 8.7 mg/dL; P = 0.004) as well as a greater absolute decrease in PZC during the depletion period (39.7 6 14.3 vs. 23.8 6 15.2 mg/dL; P = 0.01). Supplemental Figure 1 shows longitudinal change in PZC among those who did not (A) and did (B) develop clinical signs during the depletion period.
By using ROC plots, the AUC was 0.93 (95% CI: 0.83, 1.00; P < 0.0001), indicating an excellent ability of PZC to discriminate among those with and without clinical signs across a range of PZC cutoffs (Fig. 2) . The sensitivity and specificity of using a cutoff PZC of 50 mg/dL to predict the presence of clinical signs of zinc deficiency were 88% and 92%, respectively.
Acrodermatitis enteropathica. The flow diagram for the identification of relevant articles is shown in Supplemental Figure 2 . A total of 229 articles were initially identified and reviewed, of which 65 met the inclusion criteria and 55 reported on novel cases. From these articles, PZCs were available for 138 individuals (82 symptomatic only, 2 asymptomatic only, 54 both symptomatic and asymptomatic) ranging in age from <1 mo to 43 y; 48.9% were infants (<1 y of age) and 49.5% were male.
Among individuals exhibiting clinical signs, PZC was 38.2 6 20.7 mg/dL (Fig. 3A) and did not differ by age (P = 0.56) or sex (P = 0.73). The most commonly reported specific clinical signs were dermatologic lesions (98%), diarrhea (54%), and alopecia (49%). Thirty-six percent of individuals had the ''classic triad'' of all 3 of the aforementioned clinical signs; an additional 33% of individuals presented with 2 of these signs. Infants (<1 y of age) tended to be more likely to have reported alopecia (P = 0.061), diarrhea (P = 0.054), and neurological signs (P = 0.045) and less likely to have ophthalmic signs (P = 0.011) than children ($1 y of age) and adults. Bivariate comparisons indicated that PZCs did not differ on the basis of the presence or absence of particular clinical signs, nor were they associated with the number of signs present.
Six articles reported PZCs longitudinally for 16 individuals at $3 time points, with the resolution or reoccurrence of clinical signs taking place between measures (16) (17) (18) (19) (20) (21) . Four of these studies were quasi-experimental and involved changes in treatment regimens over the course of 3-18 mo. One study was specifically designed as a controlled experimental trial to examine the relation between PZC and clinical signs in patients with AE (with and without treatment) (16) . Among individuals who were undergoing effective therapeutic treatment that was subsequently withdrawn, clinical signs reappeared within 1 wk to 3 mo, at which time PZCs among all individuals were <65.0 mg/dL (range: 10.0-64.4 mg/dL). Among some individuals with interim measures, PZCs fell considerably below normal concentrations (range: 26.6-46.1 mg/dL; 4 individuals) 2-6 wk before the onset of clinical signs (16, 17) .
Among all individuals (cross-sectional and longitudinal analyses), treatment with high-dose zinc supplements (range: ;1-10 mg elemental zinc Á kg 21 Á d 21 or ;110-660 mg zinc sulfate/d) was associated with a rapid improvement or resolution of clinical signs within 1 wk and a significant increase in PZC (mean 6 SD increase in PZC: 66.3 6 35.5 mg/dL; P < 0.0001; n = 54). The PZC during supplementation was 102 6 34.7 mg/dL (Fig. 3A) . Generalized linear mixed models indicated that with progressively lower PZC, there was an increased likelihood of clinical signs being present; for every 1-SD decrease in PZC, the odds of having clinical signs increased by a factor of 27.6 (95% CI: 10.4, 72.9; P < 0.0001) (Fig. 3B) . By using ROC plots, the AUC was 0.93 (95% CI: 0.87, 0.99; P < 0.0001), indicating an excellent ability of PZC to discriminate among those with and without clinical signs, across a range of PZC cutoffs (Fig. 4) . The sensitivity and specificity of using a PZC cutoff of 50 mg/dL to predict clinical signs of zinc deficiency were 80% and 89%, respectively.
Discussion
The results of these analyses indicate that there is a clear relation between the prevalence of clinical signs of severe zinc deficiency and PZC, with an increased probability of clinical signs occurring among individuals with a lower PZC. This relation exists among both previously healthy individuals exposed to severe dietary zinc restriction and individuals with AE, an inborn error of zinc metabolism resulting in poor intestinal absorption of zinc and secondary zinc deficiency. Among those exhibiting clinical signs, the mean PZC was <40 mg/dL in both sets of study participants. This relation between clinical signs and PZC is supported by a review of the clinical and laboratory diagnosis of AE (22) , as well as by reports of low PZC among premature infants with transient symptomatic zinc deficiency and among exclusively breast-fed infants whose mothers have a mutation in the solute carrier family 30 (zinc transporter), member 2 (SLC30A2) gene [zinc transporter 2 (ZnT2)], which results in reduced zinc secretion gene into the breast milk (23) (24) (25) (26) (27) .
In the present analyses, individuals participating in the zinc depletion studies who developed clinical signs had lower mean basal PZC and a greater reduction in PZC (typically >50% within 12-36 d) during the depletion period, compared with those who did not develop clinical signs. Thus, it is possible that the onset of clinical signs is related not only to the absolute low PZC attained but also to the individualÕs baseline zinc status (reflective of recent intake) and/or velocity at which PZC changes (speed at which homeostatic mechanisms are overcome), possibly representing genetic variability in homeostatic mechanisms, although further research is necessary (28) . These results indicate that it might be advisable to maintain a higher PZC within the physiologic range (;65-125 mg/dL, depending on age, sex, and fasting status) (3, 29) to reduce vulnerability during periods of dietary inadequacy. This conclusion is further supported by a study conducted in individuals with AE, which found that after the withdrawal of high-dose zinc supplements, the duration of the interval before reoccurrence of clinical signs was typically longer among individuals with a higher PZC (16) . In addition, the present longitudinal analyses indicated that among individuals for whom there were multiple measures of PZC, a decrease in PZC appears to precede the development of clinical signs among both individuals undergoing experimental zinc depletion as well as individuals with AE.
Although PZC in the present analyses discriminated disease status (clinical signs of zinc deficiency), there was an overlap in the distributions of PZC between those who did and did not develop clinical signs (depletion-repletion studies) and among individuals when symptomatic or asymptomatic (AE cases). There may be variation in the concentration of plasma zinc that is associated with the development of symptoms among individuals. In addition, given the nonspecific nature of signs of zinc deficiency (e.g., dermatitis, diarrhea), it is possible that the occurrence of clinical signs attributed to zinc deficiency in some individuals in the zinc depletion-repletion studies was not, in fact, due to zinc deficiency, despite attempts to minimize misclassifications by having standardized inclusion and exclusion criteria. Compared with the zinc-depletion studies, we observed larger variations in PZC among the case reports of individuals with AE, with and without clinical signs. Additional factors contributing to this variation may include specimen contamination resulting from limited controls on sample collection, processing and analysis in the clinical setting, variable sample collection times after the onset of symptoms and the initiation of treatment, and varying doses of therapeutic zinc among treated individuals. It should also be noted that highdose zinc supplements provided to individuals with AE may have led to PZCs that were artificially elevated above the normal physiologic range in ;25% of individuals with AE.
This overlap in distributions of PZC among individuals with and without clinical signs complicates the determination of a single cutoff for PZC below which individuals have clinical signs associated with zinc deficiency. In the present analyses, the median PZC was ;40 mg/dL among those with clinical signs; however, logistic regression analyses and kernel density estimate plots indicated an increase in the incidence of clinical signs as PZC decreased below ;70 mg/dL among individuals participating in the zinc-depletion studies and below ;95 mg/dL among individuals with AE. It is possible that this discrepancy in the increased probability of clinical signs by PZC is the result of spurious measures of PZC among individuals with AE (resulting from the aforementioned methodologic factors) or may be due to variant AE, as has been postulated by some authors, which results in the presence of clinical signs without a concomitant decrease in PZC (30) (31) (32) . In addition, it is possible that individuals with AE who have been experiencing severely altered zinc metabolism for an extended period are more likely to develop clinical signs at a higher PZC than previously healthy individuals participating in short-term clinical zinc-depletion trials. In light of these results, it appears that the existing statistically defined lower cutoffs for PZC based on NHANES II data remain useful for identifying those with an increased risk of zinc deficiency (4) . In addition, the higher prevalence of clinical signs with a PZC <50 mg/dL in the present analyses indicates that this cutoff can be applied to indicate severe clinical deficiency. Several expert groups and international agencies have recommended the use of PZC as a biomarker of zinc status on the basis of consistent changes in PZC that have been observed after supplementation, a strong correlation between changes in total body zinc content and changes in PZC, and the availability of reference data that can be used to define zinc deficiency (2, 3) . The present analyses further validate the utility of PZC as a biomarker of severe zinc undernutrition by demonstrating a clear association between the prevalence of clinical signs associated with zinc deficiency and PZC among 2 different populations of individuals: presumably healthy adults undergoing periods of highly controlled experimental severe dietary zinc restriction and individuals with AE, a rare genetic disorder. These analyses address an important knowledge gap by defining severe zinc deficiency. Further research is necessary to understand the heterogeneity of response to severe dietary zinc restriction within and among populations. Additional research in individuals with chronically inadequate zinc intakes and chronically low PZC (i.e., populations in low-income countries) is of particular importance to understand the generalizability of these cutoffs for populations at risk of zinc deficiency due to inadequate dietary zinc intake and/or a high burden of disease. Plasma zinc and clinical zinc deficiency 1209
